PMID- 24039429
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130916
LR  - 20220316
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 9
DP  - 2013
TI  - The efficacy and safety of bupropion sustained-release formulation for the 
      treatment of major depressive disorder: a multi-center, randomized, double-blind, 
      placebo-controlled study in Asian patients.
PG  - 1273-80
LID - 10.2147/NDT.S48158 [doi]
AB  - This study was conducted to compare the efficacy and safety of bupropion 
      sustained-release (SR) formulation orally administered at daily doses of 150 
      mg/day (once daily) and 300 mg/day (150 mg twice daily) for 8 weeks versus 
      placebo in Asian patients with major depressive disorder. The mean change from 
      baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 
      8 was compared between each of the bupropion SR dose groups and the placebo group 
      using an analysis of covariance with the multiplicity adjustment by Dunnett's 
      step-down procedure. A total of 569 subjects met all of the inclusion criteria 
      and proceeded to the treatment phase. The subjects proceeding to the treatment 
      phase included 454 Japanese patients and 115 Korean patients. There was no 
      statistically significant difference between each of the bupropion SR dose groups 
      and the placebo group in the primary efficacy endpoint of change from baseline in 
      MADRS total score at week 8. Similar results were generally obtained for all of 
      the secondary efficacy endpoints. The secondary analysis and the other subgroup 
      analysis did not show a statistically significant difference in efficacy. There 
      was no substantial difference in the type, severity, and incidence of adverse 
      events (AEs) between the bupropion SR dose groups and the placebo group, which 
      indicates a favorable safety profile for bupropion SR. There were no significant 
      findings in subjects treated with bupropion SR in regard to sexual dysfunction, 
      weight change, and withdrawal syndrome, which are frequently recognized as 
      clinical concerns associated with selective serotonin reuptake inhibitors, widely 
      used for the treatment of depression.
FAU - Koshino, Yoshifumi
AU  - Koshino Y
AD  - Iris Medical Clinic, Kanazawa University, Ishikawa, Japan.
FAU - Bahk, Won-Myong
AU  - Bahk WM
FAU - Sakai, Hideaki
AU  - Sakai H
FAU - Kobayashi, Takayuki
AU  - Kobayashi T
LA  - eng
PT  - Journal Article
DEP - 20130828
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC3770623
OTO - NOTNLM
OT  - Japan
OT  - Korea
OT  - bupropion SR
OT  - major depressive disorder
OT  - placebo
EDAT- 2013/09/17 06:00
MHDA- 2013/09/17 06:01
PMCR- 2013/08/28
CRDT- 2013/09/17 06:00
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2013/09/17 06:01 [medline]
PHST- 2013/08/28 00:00 [pmc-release]
AID - ndt-9-1273 [pii]
AID - 10.2147/NDT.S48158 [doi]
PST - ppublish
SO  - Neuropsychiatr Dis Treat. 2013;9:1273-80. doi: 10.2147/NDT.S48158. Epub 2013 Aug 
      28.